ATYR (aTyr Pharma) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 08, 2026)


ATYR aTyr Pharma Inc ATYR
14 GF Score
Price $0.60
GF Value $0.46
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma 5-Year Yield-on-Cost %?

aTyr Pharma ATYR -7.43% 14 5-Year Yield-on-Cost % is 0.00 as of Jul. 08, 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 153 Biotechnology companies, aTyr Pharma ranks worse than 653594.12% on this metric.

aTyr Pharma's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for aTyr Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:



ATYR's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

aTyr Pharma  (NAS:ATYR) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


aTyr Pharma 5-Year Yield-on-Cost % Related Terms


ATYR vs DWTX, CNTX, INKT: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, aTyr Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's 5-Year Yield-on-Cost % falls into.


ATYR
14GF Score
aTyr Pharma Inc ATYR
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

aTyr Pharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of aTyr Pharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
aTyr Pharma (ATYR) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #999999 out of 153 companies in the Biotechnology industry.
Is aTyr Pharma's 5-Year Yield-on-Cost % too high?
aTyr Pharma's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, aTyr Pharma ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's 5-Year Yield-on-Cost % compare to DWTX and CNTX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places aTyr Pharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.60 — trading 31.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is aTyr Pharma (ATYR) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of $0.60 is trading 31.4% above its estimated GF Value™ of $0.46. GuruFocus considers aTyr Pharma to be Significantly Overvalued.

Key valuation signals for ATYR:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $0.46 vs. price of $0.60 (31.4% above fair value)
  • GF Score™: 14/100 with 4 warning signs

No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


aTyr Pharma Business Description

Other Exchanges 471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score

Get the complete analysis for ATYR

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$0.46
GF Value